Dennis Gilbert, Clive Brown

Aug 07, 2007

Premium

Dennis Gilbert has left his position as chief scientific officer and vice president for research at Applied Biosystems as of Aug. 1, a company spokesman confirmed last week. Gilbert resigned to “pursue other career interests,” said the spokesman, who was unable to provide further information on Gilbert’s plans or whether the company is seeking a replacement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Pushed Aside

The New York Times Magazine examines gender discrimination at the Salk Institute.

Dismissals at MD Anderson

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

Looking Into It

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

This Week in PLOS

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.

Featured White Papers

BlueBee Data Security & Compliance

The Ultimate Guide to Mouse Clinical Trials

Apr

30

Featured Webinar

Novel Methods for Improving De Novo Transcriptome Annotation with Long-Read Transcript Sequencing

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

May

08

Featured Webinar

OncoBEAM ctDNA Testing for Early Response Prediction and Therapy Surveillance in Melanoma and Pancreatic Cancer

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.

Menu